Muscarinic Acetylcholine Receptor M4 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Muscarinic Acetylcholine Receptor M4 (CHRM4)- Pipeline Review, H2 2019’, provides in depth analysis on Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology under development targeting Muscarinic Acetylcholine Receptor M4 (CHRM4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)

– The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects

– The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Anavex Life Sciences Corp

AstraZeneca Plc

Cerevel Therapeutics LLC

Karuna Therapeutics Inc

NeuroHealing Pharmaceuticals Inc

NeuroSolis Inc

Presbyopia Therapies LLC

Sosei Heptares

Suven Life Sciences Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M4 (CHRM4) Overview

Muscarinic Acetylcholine Receptor M4 (CHRM4) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M4 (CHRM4) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M4 (CHRM4) Companies Involved in Therapeutics Development

Anavex Life Sciences Corp

AstraZeneca Plc

Heptares Therapeutics Ltd

Karuna Pharmaceuticals Inc

NeuroHealing Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Muscarinic Acetylcholine Receptor M4 (CHRM4) Drug Profiles

(aceclidine + tropicamide) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(trospium chloride + xanomeline) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANAVEX-273 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANAVEX-273 + donepezil hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-0016878 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0527 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0527f Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0559 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0559f Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tropicamide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467154 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-6000918 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscarinic Acetylcholine Receptor M4 (CHRM4) Dormant Products

Muscarinic Acetylcholine Receptor M4 (CHRM4) Discontinued Products

Muscarinic Acetylcholine Receptor M4 (CHRM4) Product Development Milestones

Featured News & Press Releases

Apr 17, 2018: Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX2-73 in Rett Syndrome

Mar 07, 2018: Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)

Jan 16, 2018: Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX2-73 Published in The Journal of Clinical Hypertension

Nov 04, 2017: Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX2-73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting

Oct 30, 2017: Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Conference

Oct 27, 2017: Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017

Oct 12, 2017: Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX2-73 in Mild-to-Moderate Alzheimer’s disease Patients

Sep 05, 2017: Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX 2-73

Aug 31, 2017: First Subject Dosed in Phase 1 Clinical Study of Novel Selective MUSCARINIC M4 Agonist in Development to Treat Major Symptoms of Alzheimers Disease

Jul 20, 2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board

May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference

May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings

Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017

Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimers

Dec 08, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s disease Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Anavex Life Sciences Corp, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by Cerevel Therapeutics LLC, H2 2019

Pipeline by Karuna Therapeutics Inc, H2 2019

Pipeline by NeuroHealing Pharmaceuticals Inc, H2 2019

Pipeline by NeuroSolis Inc, H2 2019

Pipeline by Presbyopia Therapies LLC, H2 2019

Pipeline by Sosei Heptares, H2 2019

Pipeline by Suven Life Sciences Ltd, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports